Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Baloxavir marboxil - Roche/Shionogi

Drug Profile

Baloxavir marboxil - Roche/Shionogi

Alternative Names: RG 6152; RG 6152-1; S 033188; XOFLUZA

Latest Information Update: 09 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shionogi
  • Developer Roche; Shionogi
  • Class Antivirals; Dibenzothiepins; Esters; Morpholines; Pyridines; Small molecules; Triazines
  • Mechanism of Action Endonuclease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Influenza A virus infections; Influenza B virus infections; Influenza virus infections
  • Preclinical Influenza A virus H5N1 subtype

Most Recent Events

  • 04 Dec 2019 Preregistration for Influenza virus infections (In adolescents, In the elderly, In adults) in European Union (PO) prior to December 2019
  • 25 Nov 2019 Launched for Influenza A virus infections (In adolescents, In the elderly, In adults) in Taiwan (PO)
  • 25 Nov 2019 Launched for Influenza B virus infections (In adolescents, In the elderly, In adults) in Taiwan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top